Equity Research Insurance Brokers

Should You Buy Accelerant Holdings Stock in 2026?

By CirclFi Research Team · · Updated · 2/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Accelerant Holdings (ARX) carries a solid Quality of Company rating of 6.1/10. Trading at $19.81, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 2 CirclFi valuation models project upside for Accelerant Holdings (ARX) at $19.81 — the model consensus leans bearish, with a Quality Score of 6.1/10 and Value-Trap risk of 20/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 2 of 2 models suggest overvaluation — majority bearish
  • Quality Score: 6.1/10 — Moderate — mixed signals
  • Value Trap Risk: 20/100 — Minimal — healthy fundamentals
  • Fair Value Range: $16.04 – $19.38 (21% spread)

Bullish Models

0 / 2

Bearish Models

2 / 2

Quality Score

6.1 /10

Moderate — mixed signals

Value Trap Risk

20 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

2 /13
Active Models

Avg. confidence: 24%

What Is the Investment Case for Accelerant Holdings (ARX) in 2026?

What Is the Bull Case vs the Bear Case for Accelerant Holdings (ARX)?

Bull case versus bear case for Accelerant Holdings (ARX) at $19.81, derived from 2 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $16.04 target (-19.0%)
No active model projects meaningful upside for ARX at $19.81. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $16.04 (-19.0%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: investment portfolio risk represents a meaningful risk for Accelerant Holdings and its Insurance Brokers peers.

How Does ARX Compare to Its Insurance Brokers Peers?

EHTH eHealth, Inc.
7.2
BWIN The Baldwin Insuranc
6.0
HUIZ Huize Holding Limite
7.3
ZBAO Zhibao Technology In
5.5
LIFE Ethos Technologies I
7.5
AIFU AIFU Inc.
5.2
EZRA Reliance Global Grou
4.0
BRO Brown & Brown, Inc.
8.3

Valuation data pages: EHTH · BWIN · HUIZ · ZBAO · LIFE · AIFU · EZRA · BRO · TWFG · CRVL · ERIE

Which Other Stocks Score Like ARX on Quality?

Closest companies to ARX’s Quality of Company score of 6.1/10, across all industries.

Why Do CirclFi’s 2 Models Disagree on ARX?

Spread

21%

Fair Value Range

$16.04 – $19.38

A tight 21% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

FTNN

$19.38 (-2.2%)

Most Bearish

Regime Cross

$16.04 (-19.0%)

What Are the Biggest Risks of Buying ARX Stock?

Bearish Consensus

2/2 models suggest overvaluation.

Macro/Sector Risk

Insurance Brokers headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ARX Data Page →

So Is Accelerant Holdings (ARX) Worth Buying in 2026?

Our models don't have a clear verdict on Accelerant Holdings. At $19.81 vs. $17.71 median fair value, the median upside of -10.6% masks significant model disagreement (+16.8% spread). With quality at 6.1/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.

These are quantitative model outputs, not investment recommendations. Accelerant Holdings's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About ARX Stock?

Should I buy ARX stock right now?

Based on CirclFi's multi-model analysis, 0 of 2 models see upside for ARX at $19.81. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Accelerant Holdings?

Key risks include: limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Insurance Brokers companies. Always diversify and consult a financial advisor.

How does ARX compare to its competitors?

Among Insurance Brokers peers, ARX holds a Quality Score of 6.1/10. Comparable companies include EHTH (QOC 7.2), BWIN (QOC 6.0), HUIZ (QOC 7.3). The relative ranking helps investors identify whether ARX offers better fundamental quality than alternatives in the same sector.

Is ARX a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ARX's Quality Score of 6.1/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy ARX at?

CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $16.04 to $19.38. At $19.81, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ARX.

View ARX Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →